<i>ESR1</i> Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

ESR1 mutations, while rare overall in treatment-naïve endometrial cancer, are more prevalent in patients with NSMP low-grade endometrioid endometrial cancer, potentially affecting AI efficacy. ESR1 status should be considered in selecting hormonotherapy and as a stratification factor in AI trials.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-01-08
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2758
Primary Topic
Estrogen and related hormone effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

A. Leary, Corina Cornila, Coriolan Lebreton, P. Fournel et al.
Clinical Cancer Research
Estrogen and related hormone effects
article

ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial

A. Leary, Corina Cornila, Coriolan Lebreton, P. Fournel, Guillaume Beinse, F. Blanc-Durand, Elise Bonnet, Patrick Bouchaert, Yolanda Fernandez Diez, Guillaume Meynard, Emilie Kaczmarek, D. Duliege, F. Selle, David Church, S. Nikolaev, Antoine Arnaud, Philippe Follana, L. Bengrine Lefevre, Pierre-Emmanuel Brachet, Catherine Genestie, Isabelle Cojean Zelek, Raphael Leman, Florence Joly, Marie Ange Mouret-Reynier, Anne-Claire Hardy-Bessard, Jérôme Alexandre, Sophie Roche, Olivier Tredan
article en

Abstract

ESR1 mutations, while rare overall in treatment-naïve endometrial cancer, are more prevalent in patients with NSMP low-grade endometrioid endometrial cancer, potentially affecting AI efficacy. ESR1 status should be considered in selecting hormonotherapy and as a stratification factor in AI trials.

Clinical Cancer ResearchVol. 32(5)
Université d'Orléans (FR), Inserm (FR), Université d'Avignon et des Pays de Vaucluse (FR), CEA Valduc (FR), Institut Gustave Roussy (FR), University of Oxford (GB), Centre Hospitalier Universitaire de Besançon (FR), Hôpital Cochin (FR), Centre Georges François Leclerc (FR), Centre François Baclesse (LU), Centre Hospitalier Universitaire de Nîmes (FR), Centre Léon Bérard (FR), Délégation Centre-Est (FR), Centre Hospitalier Universitaire de Poitiers (FR), Groupe Hospitalier Mutualiste de Grenoble (FR), Groupe Hospitalier Diaconesses Croix Saint-Simon (FR), Institut Génétique Nantes Atlantique (FR), Laboratoire Informatique d'Avignon (FR), Centre François Baclesse (FR), Centre Jean Bernard (FR), Centre Jean Perrin (FR), Centre Oscar Lambret (FR), Institut Bergonié (FR), Arcagy Gineco (FR), Centre hospitalier universitaire d'Orléans (FR), Centre Hospitalier René-Dubos (FR), Eau de Paris (France) (FR), Centro Universitário Carioca (BR), Centre Antoine Lacassagne (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Hôpital Intercommunal de Créteil (FR), Université Grenoble Alpes (FR)
Good health and well-being
Openalex Percentile: Top 93%
Estrogen and related hormone effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.